Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16273636 | 0.90 | MRGPRX4 (0.34) | MRGPRX4S1PR1S1PR5FFAR4FFAR1 | |
| SCHEMBL16911932 | 0.88 | MRGPRX4 (0.35) | MRGPRX4PTGER1 | |
| SCHEMBL17600283 | 0.88 | MRGPRX4 (0.33) | MRGPRX4S1PR1S1PR5MAPTL3MBTL1 | |
| SCHEMBL16385364 | 0.85 | MRGPRX4 (0.37) | MRGPRX4S1PR1S1PR5MAPTPTGER1 | |
| SCHEMBL15856695 | 0.85 | FFAR4 (0.37) | MRGPRX4FFAR4FFAR1L3MBTL1PTGER1 | |
| SCHEMBL17744706 | 0.85 | MRGPRX4 (0.36) | MRGPRX4S1PR1S1PR5FFAR4MAPT | |
| SCHEMBL19987549 | 0.84 | HPGD (0.35) | MRGPRX4S1PR1S1PR5FFAR4FFAR1 | |
| SCHEMBL16385577 | 0.84 | P2RX7 (0.36) | MRGPRX4S1PR1S1PR5FFAR4FFAR1 | |
| SCHEMBL16385510 | 0.84 | MRGPRX4 (0.36) | MRGPRX4S1PR1S1PR5MAPTL3MBTL1 | |
| SCHEMBL17788098 | 0.84 | P2RX7 (0.38) | MRGPRX4S1PR1S1PR5FFAR4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3006440-B1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL CO (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9675072-B2 | Tetrazolinone compound and application of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9675072-B2 | Tetrazolinone compound and application of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9675072-B2 | Tetrazolinone compound and application of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-13 | — | — | US | disclosed |
| EP-3006440-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | Sumitomo Chemical Company Limited (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| WO-2014192953-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | 住友化学株式会社 (JP) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | CYP2E1, MT-CO2, CASP3 | MRGPRX4 2185/4885S1PR1 2749/4885S1PR5 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.